ABLIVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1648 SEK | +1.10% |
|
+3.26% | -32.87% |
| 02-23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 222M 20.33M 1.63B |
|---|---|---|---|---|---|
| Net income 2024 * | -142M -12.98M -1.04B | Net income 2025 * | -157M -14.35M -1.15B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 124M 11.33M 907M | Net cash position 2025 * | 173M 15.81M 1.27B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.1
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.10% | ||
| 1 week | +3.26% | ||
| Current month | +1.60% | ||
| 1 month | +2.36% | ||
| 3 months | -31.19% | ||
| 6 months | -26.76% | ||
| Current year | -32.87% |
1 week
0.16
0.18
1 month
0.140.18
Current year
0.140.27
1 year
0.140.32
3 years
0.140.79
5 years
0.142.68
10 years
0.1482.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 02/02/21 |
Eskil Elmér
FOU | Founder | 54 | 31/01/00 |
| Director of Finance/CFO | 57 | 30/11/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 27/04/16 | |
David Bejker
BRD | Director/Board Member | 49 | 26/04/17 |
Eskil Elmér
FOU | Founder | 54 | 31/01/00 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.1648 | +1.10% | 662,886 |
| 25/04/24 | 0.163 | +1.88% | 932,598 |
| 24/04/24 | 0.16 | -5.33% | 1,582,808 |
| 23/04/24 | 0.169 | +1.93% | 1,307,990 |
| 22/04/24 | 0.1658 | +3.88% | 2,787,638 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
20/05/2024
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.87% | 20.28M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABLI Stock
